For the quarter ending 2026-03-31, OSCR had $2,025,127K increase in cash & cash equivalents over the period. $2,610,186K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 679,023 | -352,434 | -137,484 | -228,491 |
| Deferred taxes | -6,204 | 2,624 | -175 | -36 |
| Net realized gain on sale of financial instruments | 4 | 37 | 1,171 | 12 |
| Depreciation and amortization expense | 7,018 | 7,880 | 7,312 | 6,970 |
| Amortization of debt issuance costs | 1,015 | 856 | 385 | 195 |
| Stock-based compensation expense | 15,969 | 18,085 | 20,485 | 24,109 |
| Net accretion of investments | 7,077 | 6,727 | 7,399 | 7,994 |
| Non-cash inducement payment for convertible note conversion (note 9) | - | 13,336 | - | - |
| Change in provision for credit losses | -55 | -54 | -70 | -15,300 |
| Premiums and accounts receivable | - | -2,908 | -19,970 | -39,415 |
| Receivables from cms | 86,165 | - | - | - |
| Risk adjustment transfer receivable | - | -36,516 | 4,964 | 491 |
| Accounts receivable | 224,288 | - | - | - |
| Reinsurance recoverable | 42,737 | -59,641 | -33,307 | 5,151 |
| Other assets | -5,344 | -2,643 | 3,247 | 13,247 |
| Benefits payable | 278,666 | -109,010 | 12,763 | 86,054 |
| Premium deficiency reserve | - | 0 | 0 | 0 |
| Payables to cms | 1,993,149 | - | - | - |
| Accounts payable and other liabilities | -2,007 | 93,890 | -30,010 | -58,019 |
| Unearned premiums | 5,800 | 89,087 | 7,627 | -1,408 |
| Reinsurance payable | 1,533 | -3,696 | -6,105 | -10,263 |
| Risk adjustment transfer payable | - | 816,395 | -875,882 | 692,736 |
| Net cash provided by operating activities | 2,618,980 | 671,903 | -964,658 | 509,067 |
| Purchase of investments | 914,842 | 233,245 | 172,835 | 270,969 |
| Sale of investments | 35,000 | 0 | 118,470 | 0 |
| Maturity and paydowns of investments | 299,243 | 192,551 | 210,754 | 111,513 |
| Purchase of property, equipment and capitalized software | 8,794 | 9,062 | 9,007 | 9,277 |
| Change in restricted deposits | 860 | -1,050 | -2,699 | -526 |
| Net cash used in investing activities | -590,253 | -48,706 | 150,081 | -168,207 |
| Proceeds from long-term debt | - | 0 | 410,000 | - |
| Payments of debt issuance costs | 4,739 | 225 | 22,677 | - |
| Inducement payment for convertible note conversion | - | 4,445 | - | - |
| Purchase of capped calls related to convertible notes | - | 0 | 34,440 | - |
| Tax payments related to net settlement of share-based awards | 0 | 0 | 1,746 | 1,434 |
| Proceeds from exercise of stock options | 1,139 | 12,841 | 12,897 | 23,567 |
| Proceeds from joint venture contribution | - | 0 | - | - |
| Net cash (used in) provided by financing activities | -3,600 | 8,171 | 364,034 | 22,133 |
| Increase in cash, cash equivalents and restricted cash equivalents | 2,025,127 | 631,368 | -450,543 | 362,993 |
| Cash, cash equivalents, restricted cash and cash equivalentsbeginning of period | 2,804,123 | -621,637 | -1,072,180 | 1,551,118 |
| Cash, cash equivalents, restricted cash and cash equivalentsend of period | 4,829,250 | 631,368 | -450,543 | 2,623,298 |
Oscar Health, Inc. (OSCR)
Oscar Health, Inc. (OSCR)